Evaluating robotic surgery for liver tumor removal
Official title: A Study to Evaluate Safety and Feasibility of Robotic Liver Resection
Run by Zhejiang University · NCT06353672 · Data updated 2026-11-12
This study is testing if using robotic surgery to remove liver tumors is safer and more effective than traditional surgery methods for patients with liver tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | December 1, 2020 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | April 9, 2024 |
| Trial ID | NCT06353672 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients diagnosed with a liver tumor who are eligible for robotic liver resection.
✕Probably not a fit
Patients undergoing simultaneous malignancy resection of the colorectum or other organs may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and feasibility of robotic liver resection compared to traditional laparoscopic and open liver surgeries. It utilizes advanced robotic surgical technology to enhance precision and flexibility during liver operations, particularly in complex cases. The aim is to gather reliable data on the benefits of robotic techniques in liver surgery, addressing previous limitations in comparative studies. By focusing on patients diagnosed with liver tumors, the study seeks to provide insights into the effectiveness of robotic interventions.
Why it matters
Potential benefit: If successful, this could lead to improved surgical outcomes and recovery for patients undergoing liver tumor removal.
How similar studies have gone: Previous studies have shown limited evidence for improved outcomes with robotic liver resection compared to other surgical methods, indicating this approach is still being explored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patients were diagnosed with a liver tumor. * The patients underwent robotic liver resection. Exclusion Criteria: * The patients underwent simultaneous malignancy resection of the colorectum or other organs (except gallbladder).
Where it's running
-
First Affiliated Hospital, Medical College of Zhejiang University
Hangzhou, Zhejiang, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Everolimus-based calcineurin-free immunosuppression one year after liver transplant
This trial tests whether switching to or using everolimus with reduced calcineurin inhibitors after year one post-liver transplant can protect kidney function while maintaining graft health in adults at low rejection risk.
-
Metastatic liver cancer patient registry from multiple Chinese centers
This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.
-
Safety and how the drug behaves in adults with moderate to severe liver impairment
This study tests the safety and how INCB123667 moves through the body when taken by adults with moderate to severe liver impairment.
-
Single-probe FibroScan for measuring liver stiffness
This project will try a single-probe FibroScan to measure liver stiffness in adults with chronic liver disease and compare its results to the standard M and XL probes.
-
Using polyene phosphatidylcholine to protect the liver after hepatectomy
This test checks whether giving polyene phosphatidylcholine before surgery plus magnesium isoglycyrrhizinate after surgery better prevents liver injury in people having laparoscopic liver resection for hepatocellular carcinoma.
-
CRISPR-edited donor liver transplant to reduce rejection
This trial will try transplanting deceased-donor livers that have had key HLA genes removed with CRISPR to see if they cause less rejection in adults needing a liver transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.